Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $78
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $64 to $78.
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $64 to $78.